For its long book global healthcare firm Arcoda Capital Management is sticking to companies it believes will not be affected no matter what healthcare reform the U.S. Congress decides upon later this year—those which produce “orphan” drugs, or drugs developed specifically to treat a rare medical condition.
Michael Meyers, founder, ceo and cio, said the Arcoda Global Healthcare Fund likes companies with orphan drugs which are...
This article was originally published in Alternative Investment News.